Skip to main content
Erschienen in: Wiener Medizinische Wochenschrift 17-18/2013

01.09.2013 | main topic

Bone turnover in hyperparathyroidism

verfasst von: Katharina Kerschan-Schindl, MD

Erschienen in: Wiener Medizinische Wochenschrift | Ausgabe 17-18/2013

Einloggen, um Zugang zu erhalten

Summary

A narrow serum calcium level which is essential for many metabolic processes is regulated by the calcium-sensing receptor which regulates parathyroid hormone (PTH) release. Primary hyperparathyroidism is supposed to be the third most common endocrine disorder. Besides nephrolithiasis and an increased incidence of cardiovascular symptoms it is associated with bone loss and an increased risk of fracture. Several different classical bone turnover markers have been shown to be increased. However, there are many uncertainties in pathophysiology of PHPT. Hardly any conclusive data exist on the RANK (receptor activator of nuclear factor-kB)/RANKL (receptor activator of nuclear factor-kB ligand)/OPG (osteoprotegerin) system, cathepsin K, sclerostin, FGF-23 (Fibroblast growth factor-23), Klotho, and DKK 1 (Dickkopf 1) in patients suffering from PHPT.
Literatur
1.
Zurück zum Zitat Melton LJ III. The epidemiology of primary hyperparathyroidism in North America. J Bone Miner Res. 2002;17(Suppl 2):12–17. Melton LJ III. The epidemiology of primary hyperparathyroidism in North America. J Bone Miner Res. 2002;17(Suppl 2):12–17.
2.
Zurück zum Zitat Wermers RA, Koshla S, Atkinson EJ, et al. Incidence of primary hyperparathyroidism in Rochester, Minnesota, 1993–2011: an update on the changing epidemiology of the disease. J Bone Miner Res. 2006;21:171–7.PubMedCrossRef Wermers RA, Koshla S, Atkinson EJ, et al. Incidence of primary hyperparathyroidism in Rochester, Minnesota, 1993–2011: an update on the changing epidemiology of the disease. J Bone Miner Res. 2006;21:171–7.PubMedCrossRef
3.
Zurück zum Zitat Eriksen EF, Mosekilde L, Melsen F. Bone remodeling and balance in primary hyperparathyroidism. Bone. 1986;7:213–21.PubMedCrossRef Eriksen EF, Mosekilde L, Melsen F. Bone remodeling and balance in primary hyperparathyroidism. Bone. 1986;7:213–21.PubMedCrossRef
4.
Zurück zum Zitat Pietschmann P, Niederle B, Anvari A, et al. Serum osteocalcin levels in primary hyperparathyroidism. Klin Wochenschr. 1991;69:351–3.PubMedCrossRef Pietschmann P, Niederle B, Anvari A, et al. Serum osteocalcin levels in primary hyperparathyroidism. Klin Wochenschr. 1991;69:351–3.PubMedCrossRef
5.
Zurück zum Zitat Chen Q, Kaji H, Iu MF, et al. Effects of an excess and a deficiency of endogenous parathyroid hormone on volumetric bone mineral density and bone geometry determined by peripheral quantitative computed tomography in female subjects. J Clin Endocrinol Metab. 2003;88:4655–8.PubMedCrossRef Chen Q, Kaji H, Iu MF, et al. Effects of an excess and a deficiency of endogenous parathyroid hormone on volumetric bone mineral density and bone geometry determined by peripheral quantitative computed tomography in female subjects. J Clin Endocrinol Metab. 2003;88:4655–8.PubMedCrossRef
6.
Zurück zum Zitat Khosla S, Melton LJ III, Wermers RA, et al. Primary hyperparathyroidism and the risk of fracture: a population-based study. J Bone Miner Res. 1999;14:1700–7.PubMedCrossRef Khosla S, Melton LJ III, Wermers RA, et al. Primary hyperparathyroidism and the risk of fracture: a population-based study. J Bone Miner Res. 1999;14:1700–7.PubMedCrossRef
7.
Zurück zum Zitat Vestergaard P, Mollerup CL, Frokjaer V, et al. Chort study of risk of fracture before and after surgery for primary hyperparathyroidism. Br Med J. 2000;321:598–602.CrossRef Vestergaard P, Mollerup CL, Frokjaer V, et al. Chort study of risk of fracture before and after surgery for primary hyperparathyroidism. Br Med J. 2000;321:598–602.CrossRef
8.
Zurück zum Zitat Seibl MJ, Gartenberg F, Silverberg SJ, et al. Urinary hydroxypyridinium cross-links of collagen in primary hyperparathyroidism. J Clin Endocrinol Metab. 1992;74:481–6.CrossRef Seibl MJ, Gartenberg F, Silverberg SJ, et al. Urinary hydroxypyridinium cross-links of collagen in primary hyperparathyroidism. J Clin Endocrinol Metab. 1992;74:481–6.CrossRef
9.
Zurück zum Zitat Guo CY, Thomas WEG, Al-Dehaimi AW, et al. Longitudinal changes in bone mineral density and bone turnover in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab. 1996;81:3487–91.PubMedCrossRef Guo CY, Thomas WEG, Al-Dehaimi AW, et al. Longitudinal changes in bone mineral density and bone turnover in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab. 1996;81:3487–91.PubMedCrossRef
10.
Zurück zum Zitat Christiansen P, Steiniche T, Brixen K, et al. Primary hyperparathyroidism: biochemical markers and bone mineral density at multiple skeletal sites in Danish patients. Bone. 1997;21:93–9.PubMedCrossRef Christiansen P, Steiniche T, Brixen K, et al. Primary hyperparathyroidism: biochemical markers and bone mineral density at multiple skeletal sites in Danish patients. Bone. 1997;21:93–9.PubMedCrossRef
11.
Zurück zum Zitat Suzuki S, Fukushima T, Ami H, et al. Pre- and postoperative bone metabolism of primary hyperparathyroidism. Biomed Pharmacoth. 2000;54(Suppl 1):90–96.CrossRef Suzuki S, Fukushima T, Ami H, et al. Pre- and postoperative bone metabolism of primary hyperparathyroidism. Biomed Pharmacoth. 2000;54(Suppl 1):90–96.CrossRef
12.
Zurück zum Zitat Abe Y, Ejima E, Fujiyama K, et al. Parathyroidectomy for primary hyperparathyroidism induces positive uncoupling and increases bone mineral density in cancellous bones. Clin Endocrinol. 2000;52:203–9.CrossRef Abe Y, Ejima E, Fujiyama K, et al. Parathyroidectomy for primary hyperparathyroidism induces positive uncoupling and increases bone mineral density in cancellous bones. Clin Endocrinol. 2000;52:203–9.CrossRef
13.
Zurück zum Zitat Guo CY, Holand PA, Jackson BF, et al. Immediate changes in biochemical markers of bone turnover and circulating interleukin-6 after parathyroidectomy for primary hyperparathyroidism. Eur J Endocrinol. 2000;142:451–9.PubMedCrossRef Guo CY, Holand PA, Jackson BF, et al. Immediate changes in biochemical markers of bone turnover and circulating interleukin-6 after parathyroidectomy for primary hyperparathyroidism. Eur J Endocrinol. 2000;142:451–9.PubMedCrossRef
14.
Zurück zum Zitat Nakaoka D, Sugimoto T, Kobayashi T, et al. Evaluation of changes in bone density and biochemical parameters after parathyroidectomy in primary hyperparathyroidism. Endocrine Journal. 2000;47:231–7.PubMedCrossRef Nakaoka D, Sugimoto T, Kobayashi T, et al. Evaluation of changes in bone density and biochemical parameters after parathyroidectomy in primary hyperparathyroidism. Endocrine Journal. 2000;47:231–7.PubMedCrossRef
15.
Zurück zum Zitat Christiansen P, Steiniche T, Vesterby A, et al. Primary hyperparathyroidism: iliac crest trabecular boen volume, structure, remodeling, and balance evaluated by histomorphometric methods. Bone. 1992;13:41–9.PubMedCrossRef Christiansen P, Steiniche T, Vesterby A, et al. Primary hyperparathyroidism: iliac crest trabecular boen volume, structure, remodeling, and balance evaluated by histomorphometric methods. Bone. 1992;13:41–9.PubMedCrossRef
16.
Zurück zum Zitat Thorsen K, Kristoffersson AO, Lorentzon RP. Changes in bone mass and serum markers of bone metabolism after parathyroidectomy. Surgery. 1997;122:882–7.PubMedCrossRef Thorsen K, Kristoffersson AO, Lorentzon RP. Changes in bone mass and serum markers of bone metabolism after parathyroidectomy. Surgery. 1997;122:882–7.PubMedCrossRef
17.
Zurück zum Zitat Christiansen P, Steiniche T, Brixen K, et al. Primary hyperparathyroidism: short term changes in bone remodeling and bone mineral density following parathyroidectomy. Bone. 1999;25:237–44.PubMedCrossRef Christiansen P, Steiniche T, Brixen K, et al. Primary hyperparathyroidism: short term changes in bone remodeling and bone mineral density following parathyroidectomy. Bone. 1999;25:237–44.PubMedCrossRef
18.
Zurück zum Zitat Cortet B, Cortet C, Blanckaert F, et al. Bone ultrasonometry and turnover markers in primary hyperparathyroidism. Calcif Tissue Int. 2000;66:11–5.PubMedCrossRef Cortet B, Cortet C, Blanckaert F, et al. Bone ultrasonometry and turnover markers in primary hyperparathyroidism. Calcif Tissue Int. 2000;66:11–5.PubMedCrossRef
19.
Zurück zum Zitat Steiniche T, Christiansen P, Vesterby A, et al. Primary hyperparathyroidism: bone structure, balance, and remodeling before and 3 years after surgical treatment. Bone. 2000;26:535–43.PubMedCrossRef Steiniche T, Christiansen P, Vesterby A, et al. Primary hyperparathyroidism: bone structure, balance, and remodeling before and 3 years after surgical treatment. Bone. 2000;26:535–43.PubMedCrossRef
20.
Zurück zum Zitat Carnevale V, Pacitti MT, Pileri M, et al. Short-term effects of surgery in post-menopausal patients with primary hyperparathyroidism and normal bone turnover. Endocrinol Invest. 2001;24:575–9. Carnevale V, Pacitti MT, Pileri M, et al. Short-term effects of surgery in post-menopausal patients with primary hyperparathyroidism and normal bone turnover. Endocrinol Invest. 2001;24:575–9.
21.
Zurück zum Zitat Lumachi F, Ermani M, Basso SMM, et al. Short- and long-term changes in bone mineral density of the lumbar spine after parathyroidectomy in patients with primary hyperparathyroidism. Calcif Tissue Int. 2003;73:44–8.PubMedCrossRef Lumachi F, Ermani M, Basso SMM, et al. Short- and long-term changes in bone mineral density of the lumbar spine after parathyroidectomy in patients with primary hyperparathyroidism. Calcif Tissue Int. 2003;73:44–8.PubMedCrossRef
22.
Zurück zum Zitat Rauner M, Sipos W, Pietschmann P. Osteoimmunology. Int Arch Allergy Immunol. 2007;143:31–48.PubMedCrossRef Rauner M, Sipos W, Pietschmann P. Osteoimmunology. Int Arch Allergy Immunol. 2007;143:31–48.PubMedCrossRef
23.
Zurück zum Zitat Piedra M, Garcia-Unzueta MT, Berja A, et al. Single nucleotide polymorphisms of the OPG/RANKL system genes in primary hyperparathyroidism and their relationship with boen mineral density. BMC Med Genet. 2011;12:168–76.PubMedCrossRef Piedra M, Garcia-Unzueta MT, Berja A, et al. Single nucleotide polymorphisms of the OPG/RANKL system genes in primary hyperparathyroidism and their relationship with boen mineral density. BMC Med Genet. 2011;12:168–76.PubMedCrossRef
24.
Zurück zum Zitat Fraher U, Watson PH, Kisiel M, et al. Measurement of circulating osteoprotegerin (OPG) in human sera: inhibition of circulating OPG in osteoporotic patients treated with hPTH (1–34). 2000; ASBMR, Toronto (abstract). Fraher U, Watson PH, Kisiel M, et al. Measurement of circulating osteoprotegerin (OPG) in human sera: inhibition of circulating OPG in osteoporotic patients treated with hPTH (1–34). 2000; ASBMR, Toronto (abstract).
25.
Zurück zum Zitat Nakchbandi IA, Lang R, Kinder B, et al. The role of the receptor activator of nuclear factor-kB ligand/osteoprotegerin cytokine system in primary hyperparathyroidism. J Clin Endocrinol Metab. 2008;93:967–73.PubMedCrossRef Nakchbandi IA, Lang R, Kinder B, et al. The role of the receptor activator of nuclear factor-kB ligand/osteoprotegerin cytokine system in primary hyperparathyroidism. J Clin Endocrinol Metab. 2008;93:967–73.PubMedCrossRef
26.
Zurück zum Zitat Stilgren LS, Hegedüs LM, Beck-Nielsen H, et al. Osteoprotegerin levels in primary hyperparathyroidism: effect of parathyroidectomy and association with bone metabolism. Calcif Tissue Int. 2003;73:210–216.PubMedCrossRef Stilgren LS, Hegedüs LM, Beck-Nielsen H, et al. Osteoprotegerin levels in primary hyperparathyroidism: effect of parathyroidectomy and association with bone metabolism. Calcif Tissue Int. 2003;73:210–216.PubMedCrossRef
27.
Zurück zum Zitat Kerschan-Schindl K, Riss P, Krestan C, et al. Bone metabolism in patients with primary hyperparathyroidism before and after surgery. Horm Metab Res. 2012;44:1–6.CrossRef Kerschan-Schindl K, Riss P, Krestan C, et al. Bone metabolism in patients with primary hyperparathyroidism before and after surgery. Horm Metab Res. 2012;44:1–6.CrossRef
28.
Zurück zum Zitat Stilgren LS, Rettmer E, Hegedüs LM, et al. Skeletal changes in osteoprotegerin and receptor activator of nuclear factor-kB ligand mRNA levels in primary hyperparathyroidism: effect of parathyroidectomy and association with bone metabolism. Bone. 2004;35:256–65.PubMedCrossRef Stilgren LS, Rettmer E, Hegedüs LM, et al. Skeletal changes in osteoprotegerin and receptor activator of nuclear factor-kB ligand mRNA levels in primary hyperparathyroidism: effect of parathyroidectomy and association with bone metabolism. Bone. 2004;35:256–65.PubMedCrossRef
29.
Zurück zum Zitat Bellido T, Ali AA, Gubrij I, et al. Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. Endocrinology. 2005;146:4577–83.PubMedCrossRef Bellido T, Ali AA, Gubrij I, et al. Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. Endocrinology. 2005;146:4577–83.PubMedCrossRef
30.
Zurück zum Zitat O’Brien CA, Plotkin LI, Galli C, et al. Control of bone mass and remodeling by PTH receptor signaling in osteocytes. PLoS ONE. 2008;3:e2942 (Zit 8 von Van Lierop AH et al Eur J Endocrinol 2010;163:833–837).PubMedCrossRef O’Brien CA, Plotkin LI, Galli C, et al. Control of bone mass and remodeling by PTH receptor signaling in osteocytes. PLoS ONE. 2008;3:e2942 (Zit 8 von Van Lierop AH et al Eur J Endocrinol 2010;163:833–837).PubMedCrossRef
31.
Zurück zum Zitat Kaji H, Imanishi Y, Sugimoto T, Seino S. Comparisons of serum sclerostin levels among patients with postmenopausal osteoporosis, primary hyperparathyroidism and osteomalacia. Exp Clin Endocrinol Diabetes. 2011;119:440–4.PubMedCrossRef Kaji H, Imanishi Y, Sugimoto T, Seino S. Comparisons of serum sclerostin levels among patients with postmenopausal osteoporosis, primary hyperparathyroidism and osteomalacia. Exp Clin Endocrinol Diabetes. 2011;119:440–4.PubMedCrossRef
32.
Zurück zum Zitat Van Lierop AH, Witteveen JE, Handy NAT, et al. Patients with primary hyperparathyroidism have lower circulating sclerostin levels than euparathyroid controls. Eur J Endocrinol. 2010;163:833–7.PubMedCrossRef Van Lierop AH, Witteveen JE, Handy NAT, et al. Patients with primary hyperparathyroidism have lower circulating sclerostin levels than euparathyroid controls. Eur J Endocrinol. 2010;163:833–7.PubMedCrossRef
33.
Zurück zum Zitat Ardawi MSM, Al-Sibiany AM, Bakhsh TM, et al. Decreased serum sclerostin levels in patients with primary hyperparathyroidism: a cross-sectional and a longitudinal study. Osteoporos Int. 2011;23(6):1789–97.PubMedCrossRef Ardawi MSM, Al-Sibiany AM, Bakhsh TM, et al. Decreased serum sclerostin levels in patients with primary hyperparathyroidism: a cross-sectional and a longitudinal study. Osteoporos Int. 2011;23(6):1789–97.PubMedCrossRef
34.
Zurück zum Zitat Munoz-Torres M, Reyes-Garcia R, Mezquita-Raya P, et al. Serum cathepsin K as a marker of bone metabolism in postmenopausal women treated with a Alendronate. Maturitas. 2009;64:188–92.PubMedCrossRef Munoz-Torres M, Reyes-Garcia R, Mezquita-Raya P, et al. Serum cathepsin K as a marker of bone metabolism in postmenopausal women treated with a Alendronate. Maturitas. 2009;64:188–92.PubMedCrossRef
35.
Zurück zum Zitat Gupta A, Winer K, Econs MJ, et al. FGF-23 is elevated by chronic hyperphosphatemia. J Clin Endocrinol Metab. 2004;89:4489–92.PubMedCrossRef Gupta A, Winer K, Econs MJ, et al. FGF-23 is elevated by chronic hyperphosphatemia. J Clin Endocrinol Metab. 2004;89:4489–92.PubMedCrossRef
36.
Zurück zum Zitat Yamashita H, Yamashita T, Miyamoto M, et al. Fibroblast growth factor (FGF)-23 in patients with primary hyperparathyroidism. Eur J Endocrinol. 2004;151:55–60.PubMedCrossRef Yamashita H, Yamashita T, Miyamoto M, et al. Fibroblast growth factor (FGF)-23 in patients with primary hyperparathyroidism. Eur J Endocrinol. 2004;151:55–60.PubMedCrossRef
37.
Zurück zum Zitat Kobayashi K, Imanishi Y, Miyauchi A, et al. Regulation of plasma fibroblast growth factor 23 by calcium in primary hyperparathyroidism. Eur J Endocrinol. 2006;154:93–9.PubMedCrossRef Kobayashi K, Imanishi Y, Miyauchi A, et al. Regulation of plasma fibroblast growth factor 23 by calcium in primary hyperparathyroidism. Eur J Endocrinol. 2006;154:93–9.PubMedCrossRef
38.
Zurück zum Zitat Kawata T, Imanishi Y, Kobayashi K, et al. Parathyroid hormone regulated fibroblast growth factor-23 in a mouse model of primary hyperparathyroidism. J Am Soc Nephrol. 2007;18:2683–8.PubMedCrossRef Kawata T, Imanishi Y, Kobayashi K, et al. Parathyroid hormone regulated fibroblast growth factor-23 in a mouse model of primary hyperparathyroidism. J Am Soc Nephrol. 2007;18:2683–8.PubMedCrossRef
39.
Zurück zum Zitat Björklund P, Krajisnik T, Akerström G, et al. Type I Membrane Klotho expression is decreased and inversely correlated to serum calcium in primary hyperparathyroidism. J Clin Endocrinol Metab. 2008;93:4152–7.PubMedCrossRef Björklund P, Krajisnik T, Akerström G, et al. Type I Membrane Klotho expression is decreased and inversely correlated to serum calcium in primary hyperparathyroidism. J Clin Endocrinol Metab. 2008;93:4152–7.PubMedCrossRef
40.
Zurück zum Zitat Guo J, Liu M, Yand D, et al. Suppression of Wnt signaling by Dkk1 attenuated PTH-mediated stromal cell response and new bone formation. Cell Metabolism. 2010;11:161–71.PubMedCrossRef Guo J, Liu M, Yand D, et al. Suppression of Wnt signaling by Dkk1 attenuated PTH-mediated stromal cell response and new bone formation. Cell Metabolism. 2010;11:161–71.PubMedCrossRef
41.
Zurück zum Zitat Bilezikian JP, Khan AA, Potts JT. On behalf of the third international workshop on the management of asymptomatic primary hyperparathyroidism. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international Workshop. J Clin Endocrinol Metab. 2009;94:335–9.PubMedCrossRef Bilezikian JP, Khan AA, Potts JT. On behalf of the third international workshop on the management of asymptomatic primary hyperparathyroidism. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international Workshop. J Clin Endocrinol Metab. 2009;94:335–9.PubMedCrossRef
42.
Zurück zum Zitat Vignali E, Picone A, Materazzi G, et al. A quick intraoperative parathyroid hormone assay in the surgical management of patients with primary hyperparathyroidism: a study of 206 consecutive cases. Eur J Endocrinol. 2002;146:783–8.PubMedCrossRef Vignali E, Picone A, Materazzi G, et al. A quick intraoperative parathyroid hormone assay in the surgical management of patients with primary hyperparathyroidism: a study of 206 consecutive cases. Eur J Endocrinol. 2002;146:783–8.PubMedCrossRef
43.
Zurück zum Zitat Christiansen P, Steiniche T, Brixen K, et al. Primary hyperparathyroidism: effect of parathyroidectomy on regional boen mienral density in Danish patients: a three-year follow-up study. Bone. 1999;25:589–95.PubMedCrossRef Christiansen P, Steiniche T, Brixen K, et al. Primary hyperparathyroidism: effect of parathyroidectomy on regional boen mienral density in Danish patients: a three-year follow-up study. Bone. 1999;25:589–95.PubMedCrossRef
44.
Zurück zum Zitat Silverberg SJ, Gartenberg F, Jacobs TP, et al. Increased bone mineral density after parathyroidectomy in primary hyperparathyroidism. J Clin Endocrinol Metab. 1995;80:729–34.PubMedCrossRef Silverberg SJ, Gartenberg F, Jacobs TP, et al. Increased bone mineral density after parathyroidectomy in primary hyperparathyroidism. J Clin Endocrinol Metab. 1995;80:729–34.PubMedCrossRef
45.
Zurück zum Zitat Marocci C, Cetami F. Primary hyperparathyroidism. N Engl J Med. 2011;365:2389–97.CrossRef Marocci C, Cetami F. Primary hyperparathyroidism. N Engl J Med. 2011;365:2389–97.CrossRef
46.
Zurück zum Zitat Kahn AA, Bilezikian JP, Kung AWC, et al. Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial. J Clin Endocrinol Metab. 2004;89:3319–25.CrossRef Kahn AA, Bilezikian JP, Kung AWC, et al. Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial. J Clin Endocrinol Metab. 2004;89:3319–25.CrossRef
47.
Zurück zum Zitat Grey AB, Stapleton JP, Evans MC, et al. Effect of hormone replacement therapy on bone mineral density in postmenopausal women with mild primary hyperparathyroidism: a randomized, controlled trial. Ann Int Med. 1996;125:360–8.PubMedCrossRef Grey AB, Stapleton JP, Evans MC, et al. Effect of hormone replacement therapy on bone mineral density in postmenopausal women with mild primary hyperparathyroidism: a randomized, controlled trial. Ann Int Med. 1996;125:360–8.PubMedCrossRef
48.
Zurück zum Zitat Lips P. Vitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications. Endocr Rev. 2001;22:477–501.PubMedCrossRef Lips P. Vitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications. Endocr Rev. 2001;22:477–501.PubMedCrossRef
49.
Zurück zum Zitat Cunningham J, Locatelli F, Rodriguez M. Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options. Clin J Am Soc Nephrol. 2011;6:913–21.PubMedCrossRef Cunningham J, Locatelli F, Rodriguez M. Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options. Clin J Am Soc Nephrol. 2011;6:913–21.PubMedCrossRef
50.
Zurück zum Zitat Ekoyan G, Levin A, Levin NW. K/DOIQI clinical practice guidelines on bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003;42:12–28, 52–57.CrossRef Ekoyan G, Levin A, Levin NW. K/DOIQI clinical practice guidelines on bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003;42:12–28, 52–57.CrossRef
51.
Zurück zum Zitat Okada M, Tominaga Y, Izumi K, et al. Tertiary hyperparathyroidism resistant o cinacalcet treatment. Ther Apher Dial. 2011;15(Suppl 1):33–7.PubMedCrossRef Okada M, Tominaga Y, Izumi K, et al. Tertiary hyperparathyroidism resistant o cinacalcet treatment. Ther Apher Dial. 2011;15(Suppl 1):33–7.PubMedCrossRef
Metadaten
Titel
Bone turnover in hyperparathyroidism
verfasst von
Katharina Kerschan-Schindl, MD
Publikationsdatum
01.09.2013
Verlag
Springer Vienna
Erschienen in
Wiener Medizinische Wochenschrift / Ausgabe 17-18/2013
Print ISSN: 0043-5341
Elektronische ISSN: 1563-258X
DOI
https://doi.org/10.1007/s10354-012-0125-9

Weitere Artikel der Ausgabe 17-18/2013

Wiener Medizinische Wochenschrift 17-18/2013 Zur Ausgabe